A PHASE II PROSPECTIVE RANDOMIZED CROSSOVER STUDY ASSESSING THE ACUTE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJ??GREN'S RELATED DRY EYE DISEASE
Latest Information Update: 30 Jul 2024
At a glance
- Drugs Lubricin (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lubris BioPharma
Most Recent Events
- 30 Jul 2024 New trial record